Table 1.
Baseline Characteristics
| Characteristic | TDF (n=733) | ZDV (n=284) | P Value |
|---|---|---|---|
| Age at second-line ART initiation, y, median (IQR) | 41.1 (33.9–50.2) | 40.4 (34.5–49.4) | .727 |
| Female sex | 381 (52) | 128 (45) | .048 |
| No school or primary school only | 431 (59) | 165 (58) | .839 |
| Living with spouse or partner | 360 (49) | 158 (56) | .062 |
| Duration of first-line EFV/TDF/3TC, y, median (IQR) | 2.6 (1.6–3.5) | 2.4 (1.6–3.5) | .850 |
| Year of second-line ART initiation | <.001 | ||
| 2012–2015 | 180 (25) | 120 (42) | |
| 2016–2018 | 553 (75) | 164 (58) | |
Data are presented as No. (%) unless otherwise indicated.
Abbreviations: 3TC, lamivudine; ART, antiretroviral therapy; EFV, efavirenz; IQR, interquartile range; TDF, tenofovir disoproxil fumarate; ZDV, zidovudine.